GI CONNECT CRC Masterclass: accredited elearning, slides and summary video

Dr Samuel J. Klempner is a GI medical oncologist with research and clinical focus on esophagogastric cancers and cancer genomics. Dr Klempner completed his residency in internal medicine at Brigham and Women’s Hospital/Harvard Medical School, followed by a combined hematology-oncology fellowship at Beth Israel Deaconess Medical Center/Harvard Medical School. While at Harvard, Dr Klempner studied the mechanisms of resistance to targeted therapies in tumor cells in the lab of Dr Lewis Cantley, PhD. Dr Klempner is board certified in medical oncology, hematology, and internal medicine. Prior to joining The Angeles Clinic and Research Institute Dr Klempner served as an Assistant Clinical Professor in the division of Hematology-Oncology at the University of California Irvine. Dr Klempner’s research interests include the intersection of genomics and immunotherapies, oncogene-driven tumors, acquired resistance, and experimental therapeutics. Dr Klempner is involved in professional societies including the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), and the European Society for Medical Oncology (ESMO).

Dr Autumn McRee is an Associate Professor of Medicine specializing in gastrointestinal (GI) medical oncology at The University of North Carolina (UNC). She graduated from the McGovern Medical School at The University of Texas in Houston and completed her Internal Medicine residency at Vanderbilt University. During her hematology/oncology fellowship at UNC, she developed an interest in GI oncology and now as faculty, has established a career dedicated to early drug development and experimental therapeutics with an emphasis in pancreatic and hepatobiliary cancers. Dr McRee demonstrates the unique combination of clinical trial productivity and correlative science knowledge that has allowed her to seamlessly bridge the gap between scientists and clinicians with a translational research focus in tissue-based research, next generation sequencing and bioinformatics. She oversees the GI clinical trials program at UNC, serving as PI for trials both industry sponsored and investigator initiated. Dr McRee also is an active member of the Alliance for Clinical Trials in Oncology and co-chairs the Hoosier Cancer Research Network GI Clinical Trials Working Group.

Prof. Shubham Pant is a Hematologist-Oncologist and an Associate Professor of Medicine at University of Texas MD Anderson Cancer Center in Houston. He previously served as the Director of Clinical Trials for the Section of Hematology-Oncology and Associate Director of the Tobacco Settlement Endowment Trust (TSET) Phase 1 program, for the Stephenson Cancer Center in Oklahoma City. Furthermore Prof. Pant was the Oncology Lead of the Clinical Research Disease Site Group for Gastrointestinal Cancers and Clinical Research Disease Site Group Chair for Hepatocellular Cancers at the same institute. Prof. Pant completed his fellowship from the Ohio State University, where he was elected Chief Fellow. He previously served as an elected member at large to the Board of Directors for Cancer and Leukemia Group B (CALGB), was the Site Principal Investigator for CALGB and was a Member of the Board of Trustees for ACTION. Prof. Pant served on the Board of Oklahoma Society of Clinical Oncology. He is a participant in the ASCO Leadership Development Program, Class of 2015-16. His awards include the Golden Pillar Award for Outstanding Patient Service in 2012 and 2014, America’s Top Doctors by Castle Connolly and Oklahoma 40 Under 40 in the Oklahoma Magazine. In 2015, he anchored a health show on CNN-IBN India titled: ‘Let’s Talk Health’.

Dr Joleen Hubbard is Deputy Director of Clinical Research and Academic Affairs for the Allina Health Cancer Institute in Minneapolis, Minnesota.  She was previously Assistant Professor of Medical Oncology at Mayo Clinic. She completed medical school and residency at the University of Minnesota and haematology/oncology training at Mayo Clinic, Rochester, Minnesota. Dr Hubbard specialises in the treatment of gastrointestinal cancers, focusing on colorectal cancer. Dr Hubbard is the PI of several phase I clinical trials, investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology with a special interest in clinical and biologic markers of frailty. She serves as a member of the Cancer in the Elderly, as well as the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network.